CRISPR Therapeutics’ CRSP Casgevy, a one-shot gene therapy, was approved in late 2023 and early 2024 across the United States ...

CRISPR Therapeutics advances with promising CTX310 data and key clinical milestones ahead. Click here to read an analysis of ...

Vertex Pharmaceuticals’ second quarter 2025 results exceeded Wall Street’s expectations, but the market responded sharply ...

As the first wave of gene therapies for transfusion-dependent β-thalassemia (TDT) continues to roll out in the U.S., a new conversation is ...

Vertex Pharmaceuticals Inc (VRTX) reports a 12% revenue increase and successful product launches, while addressing challenges ...

While Casgevy is currently the only CRISPR-based therapy, several companies are advancing gene-editing treatments using similar technology. Beam Therapeutics BEAM is developing its lead candidate ...

Vertex stock crashed late Monday after the company said it wouldn't advance a next-generation pain drug into more testing.

Crispr Therapeutics 40% share in Casgevy could result in revenue annual between $1.2 billion and $2.8 billion towards the end of the decade. See why CRSP stock is a Hold.

CASGEVY™ is a non-viral, ex vivo CRISPR/Cas9 gene-edited cell therapy for eligible patients with SCD or TDT, in which a patient’s own hematopoietic stem and progenitor cells are edited at the ...

That means Casgevy will be covered “immediately” by the IMF to speed up the rollout for up to 460 people eligible for the treatment, according to NICE. The drug carries a list price of ...

The other, Casgevy, genetically edits stem cells to do the same. Casgevy is a therapy based on CRISPR, which stands for "clustered regularly interspaced short palindromic repeats." ...